Shares of Wave Life Sciences Ltd. WVE rose sharply during Tuesday's session after the company announced interim data from its ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular ...
Results that may be inaccessible to you are currently showing.